Home › Research › Clinical trials
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial
Coleman KKL, Berry S, Cummings J, Hsiung GR, Laforce R, Huey E, Ducharme S, Tartaglia MC, Mendez MF, Onyike C, et al.. The Lancet Neurology, 2025
Topic: Brain proteins, microglia and lab models
Plain-language summary
The primary outcome was difference in the change in Neuropsychiatric Inventory apathy scores for oxytocin versus placebo periods in the per-protocol population after 6 weeks of treatment. Interpretation Intranasal oxytocin given every third day was well tolerated and was associated with a small reduction in apathy in patients with frontotemporal dementia.
What this study adds
Evidence grade: Early
The record lists 94 participants. In this phase 2 trial, intranasal oxytocin given every third day was well tolerated and was associated with a small reduction in apathy in people with frontotemporal dementia. Reported effect size: NPI apathy change -1.32 points (95% CI -2.43 to -0.21) vs placebo.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Coleman, K. K. L., Berry, S., Cummings, J., Hsiung, G. R., Laforce, R., Huey, E., et al. (2025). Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial. The Lancet Neurology. https://doi.org/10.1016/S1474-4422(24)00456-3
Vancouver
Coleman KKL, Berry S, Cummings J, Hsiung GR, Laforce R, Huey E, et al. Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial. The Lancet Neurology. 2025. doi:10.1016/S1474-4422(24)00456-3. PMID: 39862881.
BibTeX
@article{coleman2025-39862881,
author = {Coleman, K. K. L. and Berry, S. and Cummings, J. and Hsiung, G. R. and Laforce, R. and Huey, E. and Ducharme, S. and Tartaglia, M. C. and Mendez, M. F. and Onyike, C. and others},
title = {{Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial}},
journal = {The Lancet Neurology},
year = {2025},
doi = {10.1016/S1474-4422(24)00456-3},
pmid = {39862881},
url = {https://doi.org/10.1016/S1474-4422(24)00456-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The primary outcome was difference in the change in Neuropsychiatric Inventory apathy scores for oxytocin versus placebo periods in the per-protocol population after 6 weeks of treatment.
- Interpretation Intranasal oxytocin given every third day was well tolerated and was associated with a small reduction in apathy in patients with frontotemporal dementia.
Why it matters
In this phase 2 trial, intranasal oxytocin given every third day was well tolerated and was associated with a small reduction in apathy in people with frontotemporal dementia. The findings are from a per-protocol analysis.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Study designphase-2-trial
- Participants94
- Effect sizeNPI apathy change -1.32 points (95% CI -2.43 to -0.21) vs placebo
- Evidence strengthEarly
Limitations
Small effect on an informant-rated scale; crossover design with washout; only 82% completed both periods in stage 2; per-protocol primary analysis.
How this study scored 69/100
Published in a leading specialty journal, and it is a mid-stage phase 2 trial. We have no data on free to read, so that was left out: it earned 68 of the 98 points we could judge it on, which is 69 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Lancet Neurology) |
| Journal's citation record | 3 / 4 | The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29) |
| Study design | 8 / 12 | A mid-stage phase 2 trial |
| Strength of evidence | 2 / 5 | Rated “early” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 94 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 3 / 7 | Cited 18 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 6.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 11.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 18 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Elizabeth C. Finger: h-index 81 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | University of Washington: institution h-index 3,540 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 24 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39862881) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 68 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 68 of the 98 points we could judge it on is 69 out of 100. |
| Total | 69 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/S1474-4422(24)00456-3
- PubMed: 39862881
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Clinical trials from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.